We have read the paper, "Comparison of Gleason upgrading rates in transrectal ultrasound systematic random biopsies versus US-MRI fusion biopsies for prostate cancer" with great interest and appreciate the work of the authors (1). They have compared the Gleason upgrading (GU) rates and tried to determine the concordance of the Gleason scores in the biopsy versus final pathology after surgery in patients who underwent transrectal ultrasound (TRUS) systematic random biopsies (SRB) versus US-MRI FB for prostate cancer (PCa).
